Jacobio Pharmaceuticals Group Co., Ltd. · HKEX:1167
Jacobio Pharmaceuticals — H1 2022 Earnings Presentation
26 slides from Jacobio Pharmaceuticals's earnings presentation, August 2022
Slide 1: Jacobio Pharmaceuticals 2022 Interim Results
Jacobio Pharmaceuticals 2022 Interim Results
Slide 2: Focus on a patient-centric approach
以患者受益为导向 利用最新的科研成果研发全球首创新药 Focus on a patient-centric approach Develop transformative medicine through scientific breakthroughs and innovative technology
Slide 3: Our Induced Allosteric Drug Discovery Platform (IADDP)
Our Induced Allosteric Drug Discovery Platform (“IADDP”) Targeting undruggable proteins with significant clinical value, our IADDP integrates multiple proprietary techniques to: • Identify possible allosteric sites • Uncover potential allosteric mechanisms • Design novel allosteric molecules, and •
Slide 4: Advance Novel Drug Development in Key Oncogenic Pathways
Advance Novel Drug Development in Key Oncogenic Pathways SHP2 (JAB-3312, JAB-3068) • KRAS G12D (JAB-22000) KRAS G12C (JAB-21822) • Undisclosed target (JAB-BX300) KRASmulti (JAB-23400) SHP2 (JAB-3312, JAB-3068) CD73 (JAB-BX102) PARP7 (JAB-26766) • BET (JAB-8263) HER2-STING (JAB-BX400) CD73-STING (JAB
Slide 5: Our Diverse Pipeline Targeting Critical Pathways - Clinical stage & 2022 INDs
Our Diverse Pipeline Targeting Critical Pathways - Clinical stage & 2022 INDs Asset Combo Target Modalities Indications Status Pre-clinical Phase I Phase II Strategy JAB-3312/ SHP2 NSCLC, HNSCC, KRASi, PD-1, Small molecule Phase II Global JAB-3068 (RAS pathway, I/O) ESCC, ACC EGFRi KRAS G12C NSCLC,
Slide 6: Our Diverse Pipeline Targeting Critical Pathways - 2023-2024 INDs
Our Diverse Pipeline Targeting Critical Pathways - 2023 - 2024 INDs Asset Target Modalities Indications Status Lead Optimization IND-enabling KRASMULTI PDAC, CRC, JAB-23400 Small molecule 2023 IND (RAS pathway) NSCLC P53 Y220C JAB-30300 Small molecule Solid tumors 2023 IND (P53 pathway) HER2-STING J
Slide 7: Our SHP2 Inhibitor JAB-3312 as a Potential Best-in-Class Drug
Our SHP2 Inhibitor JAB-3312 as a Potential Best-in-Class Drug Preclinical comparison Clinical dose RMC-4550 JAB-3312 In-house or ref SHP2 biochemical IC50 (nM) 1.5 10.4 JAB-3312 Binding kinetics KD (nM) 0.206 13.6 1-8mg QD Cellular p-ERK IC50 in NCI-H358 (nM) 3.64 28 (ref) Cellular p-ERK IC50 in KYS
Slide 8: SHP2 Inhibitor-Global Development Plan
SHP2 Inhibitor-Global Development Plan Asset Regimen Indications Phase I Phase IIa Recent development KRAS G12C mut Phase IIa Combo w/KRAS G12Ci Global trial NSCLC initiated in Jul 2022 JAB-3312 Osimertinib progressed FPI in Combo w/EGFRi Global trial SHP2 NSCLC Jan 2022 Phase IIa Combo w/PD-1 mAb N
Slide 9: Our KRAS G12C Inhibitor JAB-21822 – 2022 ASCO Data Readout
Our KARS G12C Inhibitor JAB-21822 with the Favorable Efficacy and Safety Profile – 2022 ASCO Data Readout Phase I preliminary clinical data of JAB-21822 monotherapy trial in China, especially in NSCLC cohort, was reported at the 2022 ASCO Annual Meeting in June 2022. Waterfall Plot (as of April 1, 2
Slide 10: KRAS G12Ci JAB-21822-Global Development Plan
KRAS G12Ci JAB-21822-Global Development Plan Upcoming Milestone Asset Regimen Indications IND Phase I Phase II Pivotal Recent development （expected） Phase II 2022 2H Mono NSCLC China trial initiated with FPI (Expected) in Mar 2022 Phase IIa CRC, PDAC and other Mono China trial initiated with FPI sol
Slide 11: KRAS G12C + SHP2 - Potentially Best Combo Strategy
KRAS G12C + SHP2 - Potentially Best Combo Strategy KRAS G12C in combination with SHP2 strategy is supported by: l Robust pre-clinical data Nature Publication Ref: Jude Canon, Nature, 2019 l Jacobio’s preliminary clinical data l Preliminary clinical data presented at IASLC 2022 World Conference of Lu
Slide 12: Next Breakthrough - Jacobio's KRASmulti and KRAS G12D inhibitor
Next Breakthrough - Jacobio’s KRASmulti and KRAS G12D inhibitor Pancreatic Cancer 10% 36% KRAS mt total ～90% 36% KRAS G12D ～36% KRAS G12V ～27% 21% JAB-23400 JAB-22000 36% 25% KRAS G12R/S/A KRAS G12C ～2% 27% G13, Q61H ～21% A first-in-class, orally A small-molecule KRAS bioavailable, KRASmulti G12D in
Slide 13: Our KRASMULTI Inhibitor JAB-23400
Our KRASMULTI Inhibitor JAB-23400 Leveraging our Induced Allosteric Drug Discovery Platform (“IADDP”), we have designed JAB-23400 which can Inhibit the activity of multiple KRAS mutants in both RAS (ON) and RAS (OFF) states, including KRAS G12X (G12D, G12V, G12R, G12S and G12A), G13D and Q61H, with
Slide 14: Other Leading Pre-clinical Stage Drug Candidates – P53 Activator
Other Leading Pre-clinical Stage Drug Candidates – P53 Activator JAB-30300 is an orally available, allosteric small molecule for the treatment of patients with locally advanced or metastatic solid tumors harboring P53 Y220C mutation. Projects targeting P53 mutations other than Y220C are also under d
Slide 15: Other Leading Pre-clinical Stage Drug Candidates – PARP7 Inhibitor
Other Leading Pre-clinical Stage Drug Candidates – PARP7 Inhibitor JAB-26766 - an orally bioavailable small-molecule PARP7 inhibitor, targeting immuno-oncology pathway for the treatment of a variety of solid tumors. Role of PARP7 Strong Antitumor Effect NCI-H1373 Xenograft model 1600 Tumor Volume, m
Slide 16: Spanning from Small Molecule and Monoclonal Antibody to iADC
Spanning from Small Molecule and Monoclonal Antibody to Immunostimulatory Antibody-drug Conjugate (iADC)
Slide 17: Our iADC Programs Supported by Unique Payloads
Our iADC Programs Supported by Unique Payloads We believe the key of non-conventional ADCs is to find the optimal payload and linker. Leveraging our strength in small-molecule drug discovery and development, we have designed innovative immune- stimulator as payloads to built our immunostimulatory an
Slide 18: STING – Activate Anti-tumor Activity and Reshape the TME
STING – Activate Anti-tumor Activity and Reshape the TME MOA in Tumor Microenvironment (TME) • Immune cells — Turn “cold tumor” to “hot” - “stimulating innate and adaptive immunity through cytokines such as type I IFN, promoting the maturation and production of immune cells such as T cells, DCs, and
Slide 19: STING – Activate Anti-tumor Activity and Reshape the TME
STING – Activate Anti-tumor Activity and Reshape the TME Multiple projects in clinical stage evaluating the Intratumoral Systemic efficacy and safety of STING via injection administration Intratumoral injection / Systemic administration Restriction on tumor type, Systemic inflammation location or si
Slide 20: Our Non-CDN STING Agonist
Our Non-CDN STING Agonist Jacobio STING agonist Pharmacology studies JAB-27670 MC38 Syngeneic MC38 Xenografts Human STING WT binding 4000 Affinity 0.175nM assay/IC50 Tumor Volume (mm3) 3000 dosing stopped Human IFN-β Vehicle, p.o.,Q3D x5 17.9nM assay b/EC50 2000 JAB-27670 1mg/kg Cell-base function p
Slide 21: JAB-BX400 – a STING-iADC Product Candidate Targeting HER2
JAB-BX400 – a STING-iADC Product Candidate Targeting HER2 >1000 fold increase in potency of HER2-STING vs. Free Superior Efficacy to Trastuzumab payload (STING) SK-OV-3+PBMC co-culture SK-OV-3 Xenografts CXCL10 ELISA 1400 1.4 1200 Tumor volume, mm3 1.2 1000 Vehicle, i.v. once 1.0 JAB-BX400 Jacobio H
Slide 22: CD73 mAb (JAB-BX102) & CD73-STING iADC (JAB-X1800)
CD73 mAb (JAB-BX102) & CD73-STING iADC(JAB-X1800) JAB-BX102 CD73 mAb JAB-BX1800 CD73-STING iADC l JAB-BX102 in clinical stage - IND approved l CD73-STING iADC in lead optimization stage with FPI expected in Aug 2022 l JAB-1800 with better MDA-MB-231 cancer cell- l To combo with PD-1 in clinical kill
Slide 23: On Target to Capture the Global Market
On Target to Capture the Global Market
Slide 24: AbbVie Partnership Expedited Our Global Development
AbbVie Partnership Expedited Our Global Development Transformative Collaboration • Leverage a partner’s global clinical, regulatory, medical, patient advocacy and commercial footprint • Rights of Parties AbbVie – Worldwide (except for PRC, Hong Kong and Macau) Jacobio - PRC, Hong Kong and Macau Fina
Slide 25: Financial Information
Financial Information SELECT COMPANY FINANCIALS （RMB mm） （RMB mm） R&D costs 1 Cash, Bank Balances and Bank Credit 2, 3 221 26% 175 2021/12/31 1,538 Cash and Bank Balances Bank Credit 2022/6/30 1,567 2021 1H 2022 1H 1 R&D costs = Cost of revenue + Research and development expenses. All R&D costs in r
Slide 26: Our Expansion
Our Expansion In-house R&D Global FIC Global Headquarter Allosteric Inhibitor 6 Clinical Stage Assets (2 Global TOP 3) Beijing, China Tech Platform 15+ Pipeline Assets (9 Global TOP 3 Potential) 2022 HC: 285 employees Global Market Full Function Pharma Global Partnership License-out Deals First NDA
Jacobio Pharmaceuticals Group — H1 2022 Earnings Presentation on 6ix